Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Castrate-Resistant Prostate Cancer 1

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms × OGX-011 × Genitourinary × Clear all
NCT00138918 2017-03-03

Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

University of British Columbia

Phase 2 Completed
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT01188187 2016-10-14

SYNERGY

Achieve Life Sciences

Phase 3 Completed
1,022 enrolled
Genitourinary

Prostatic Neoplasms

NCT01578655 2016-10-12

AFFINITY

Achieve Life Sciences

Phase 3 Completed
630 enrolled
Genitourinary

Prostatic Neoplasms

NCT00327340 2012-10-05

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Achieve Life Sciences

Phase 2 Completed
70 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡